Active ingredient: 1 ml of solution contains 6 mg of liraglutide. One pre-filled pen contains 18 mg liraglutide in 3 ml
Indications: Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial
Body Mass Index (BMI) of

• ≥30 kg/m² (obese), or
• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Dosage & Administration: The starting dose is 0.6 mg daily. The dose should be increased to 3.0 mg daily in increments of 0.6 mg with at least one week interval to improve gastro-intestinal tolerability. Saxenda® is administered once daily at any time, independent of meals, subcutaneously injected in the abdomen, thigh or upper arm, preferably around the same time every day.